论文部分内容阅读
目的探讨重组人血管内皮抑制素治疗肺癌患者的临床治疗效果。方法选取2013年8月至2014年8月吉林省肿瘤医院收治的肺癌患者184例为研究对象,按随机数字表法分为观察组和对照组,每组92例。对照组患者给予常规西药治疗,观察组患者在对照组治疗的基础上给予重组人血管内皮抑制素治疗。比较两组患者的治疗效果。结果对照组患者的治疗总有效率为68.5%,观察组患者的治疗总有效率为89.1%,观察组患者的治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);观察组及对照组患者的不良反应发生率分别为4.3%、13.0%,观察组患者的不良反应发生率更低,差异有统计学意义(P<0.05)。结论采用重组人血管内皮抑制素治疗肺癌患者,可取得较好的治疗效果。
Objective To investigate the clinical effect of recombinant human endostatin on patients with lung cancer. Methods A total of 184 patients with lung cancer who were admitted to Jilin Cancer Hospital from August 2013 to August 2014 were selected as study subjects and divided into observation group and control group according to random number table method, with 92 patients in each group. Patients in the control group were treated with conventional western medicine. Patients in the observation group were treated with recombinant human endostatin on the basis of the control group. The treatment effect of two groups of patients was compared. Results The total effective rate was 68.5% in the control group and 89.1% in the observation group. The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). Adverse reactions in observation group and control group were 4.3% and 13.0%, respectively. The incidence of adverse reactions in observation group was lower, with statistical significance (P <0.05). Conclusion Recombinant human endostatin in patients with lung cancer can achieve better therapeutic effect.